NVIDIA launches Jetson Thor robotics computers for physical AI systems
SAN JOSE, Calif. - PROCEPT BioRobotics Corporation (NASDAQ:PRCT), a $3.18 billion market cap company specializing in surgical robotics, announced today that its Aquablation therapy has shown similar symptom score reduction and better preservation of ejaculatory and continence functions compared to laser enucleation for treating large prostates. The company has demonstrated impressive revenue growth of 65% over the last twelve months, according to InvestingPro data. These findings come from the WATER III trial, presented at the European Association of Urology 2025 Annual Congress.
The international, multicenter WATER III study, which treated 186 men from December 2020 to September 2024, reported three-month primary safety and efficacy endpoints. The results indicated that Aquablation therapy resulted in substantially similar symptom relief to laser enucleation while exhibiting significantly lower rates of ejaculatory dysfunction (14.8% vs. 77.1%) and stress incontinence (0% vs. 9.1%). Moreover, the procedural transfusion rate for patients undergoing Aquablation therapy was 0%.
Reza Zadno, CEO of PROCEPT BioRobotics, stated, "WATER III represents a significant milestone in our mission to establish Aquablation therapy as the standard of care for patients suffering with BPH." He highlighted the therapy’s effectiveness in symptom relief while preserving quality of life factors such as sexual function and continence. While the company maintains a strong gross profit margin of 61% and operates with moderate debt levels, InvestingPro analysis indicates that analysts don’t expect profitability this year. For detailed insights and additional ProTips about PROCEPT BioRobotics’ financial outlook, investors can access the comprehensive Pro Research Report available on InvestingPro.
Dr. Naeem Bhojani from the University of Montreal echoed these sentiments, noting the meaningful advancement Aquablation therapy represents for patients seeking BPH treatment due to its consistent efficacy and lower rates of sexual and continence dysfunction.
Aquablation therapy, the ultrasound-guided, robotic-assisted, heat-free waterjet treatment for BPH, is designed to allow personalized treatment plans tailored to each patient’s unique anatomy. The therapy’s robotic-assisted execution enables precise, targeted, and controlled removal of prostate tissue.
The company emphasizes that Aquablation therapy is becoming a globally reproducible procedure with the potential to become the BPH standard of care for all prostate sizes, supported by over 150 peer-reviewed publications and multiple randomized clinical studies. With a healthy current ratio of 9.07 indicating strong liquidity, PROCEPT BioRobotics appears well-positioned to support its growth initiatives. Investors should note that based on InvestingPro’s Fair Value analysis, the stock currently appears overvalued. The company is scheduled to report its next earnings on April 24, 2025, which could provide further insights into its commercialization progress.
This announcement is based on a press release statement from PROCEPT BioRobotics.
In other recent news, Procept BioRobotics Corp reported its fourth-quarter 2024 financial results, with revenue reaching $68.24 million, surpassing the forecast of $66.83 million. Despite this revenue beat, the company posted an earnings per share (EPS) of -$0.35, missing the expected -$0.34. The company’s full-year 2024 revenue was $224.5 million, marking a 65% year-over-year increase. Procept BioRobotics anticipates further growth, projecting a 43% revenue increase in 2025 to $320 million.
In discussions with Jefferies, Procept BioRobotics executives expressed optimism about the company’s competitive positioning and opportunities in prostate cancer treatment. Jefferies maintained a Hold rating on the stock with a price target of $77. The firm noted that the procedure environment is improving post-saline shortages, which had previously impacted volumes. Procept BioRobotics is also focused on expanding its market share in the benign prostatic hyperplasia (BPH) treatment sector, leveraging its innovative Hydros robotic system.
The company is strategically expanding internationally, with significant momentum in the UK and Japan. Despite facing challenges such as saline shortages, which delayed some procedures, Procept BioRobotics is optimistic about recovering procedure volumes. Looking ahead, the company expects to maintain a gross margin of 64.5% and projects an adjusted EBITDA loss of $35 million for 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.